Semaglutide

Join me on an exploration into the realm of pharmacology and therapeutics, where we uncover the marvels of semaglutide. As a researcher deeply immersed in this field, few substances have captivated the public this last year as semaglutide. This remarkable compound, belonging to the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), has been making waves in recent years for its promising therapeutic effects in managing type 2 diabetes mellitus (T2DM) and obesity. Let's dive into the intricacies of semaglutide, exploring its mechanisms, benefits, and potential side effects.

JR

Joel is the founder of MoveWell and IMPOSSIBLE. He became the youngest person to run an ultra marathon on every continent, and created MoveWell to make recovery easy with routines he would actually do.